Progression‐free survival at 3 years is a reliable surrogate for 5‐year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma

BACKGROUND: Despite 3‐year survival being used as a primary endpoint in some randomized controlled trials (RCTs), limited evidence supports the use of intermediate endpoints to evaluate the effect of new therapies in esophageal squamous cell cancer (ESCC). This study aimed to systematically evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yu‐Xian, Zheng, Yu‐Zhen, Gao, Tian‐Tian, Liu, Shi‐Liang, Xi, Mian, Liu, Meng‐Zhong, Wang, Jun‐Ye, Qi, Shu‐Nan, Yang, Yong, Zhao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582670/
https://www.ncbi.nlm.nih.gov/pubmed/35434962
http://dx.doi.org/10.1002/cam4.4751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582670/
https://www.ncbi.nlm.nih.gov/pubmed/35434962
http://dx.doi.org/10.1002/cam4.4751

Ejemplares similares